Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Specialties of providers primarily prescribing and managing systemic bevacizumab for HHT-related HOCF in HHT centers

From: Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers

SpecialtyPercent of Centers
Hematology50%
Pulmonology39%
Cardiology11%
Gastroenterology6%
Internal Medicine6%